Pharmaceuticals Search Engine [selected websites]

Loading

Wednesday, November 24, 2010

NovAliX acquires a majority interest in Graffinity

NovAliXStrasbourg, France -- November 16th, 2010 - GRAFFINITY'S PROPRIETARY FRAGMENT-BASED SPR DRUG DISCOVERY TECHNOLOGY WILL BE ADDED TO NOVALIX'S INTEGRATED CHEMISTRY AND BIOPHYSICAL CAPABILITIES - NovAliX SAS (“NovAliX”) announced that it has entered into a definitive agreement to acquire a majority interest in Graffinity Pharmaceuticals GmbH ("GRAFFINITY") of Heidelberg, Germany, a leading fragment based drug discovery services company. Financial details of the transaction were not disclosed.

NovAliX’ President, Stephan Jenn stated: "The acquisition of Graffinity will be a significant step toward our goal of providing integrated drug discovery services. With a unique and diverse small molecule library and patented SPR-imaging technology, the Graffinity platform is fully complementary to NovAliX’ offerings in X-Ray crystallography, supramolecular mass spectrometry and liquid-/solid-state NMR. With this second technology-oriented acquisition in 2010, we are forming a group of more than 120 scientists developing and applying cutting edge research capabilities in discovery and development of innovative medicines. We are an external innovation partner for our pharmaceutical clients."...

[...]

...About NovAliX SAS

Strasbourg, France based NovAliX Group is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry’s outsourcing needs from discovery to manufacturing. With X-ray protein crystallography, supramolecular mass spectrometry and organic chemistry NovAliX offers comprehensive integrated services in small molecule drug discovery. With advanced NMR technologies, NovAliX provides fine characterization of biologics, thorough analysis of APIs and polymorphism studies to support pharmaceutical development and manufacturing teams.
NovAliX Group, a team of 120 scientists, is located in state-of-the-art laboratory facilities in the Strasbourg-Illkirch BioParc and throughout Europe... [PDF] NovAliX's Press Release -

Wednesday, November 17, 2010

Deinove : Deinobiotics' project labelled

DeinoveMarch 22nd, 2010 - Deinobiotics, project led by Deinove in partnership with biotech company Nosopharm and two expert laboratories, CPBS (CNRS - University of Montpellier 1) and IGS (CNRS Marseille), was labelled by the Eurobiomed pole and has been selected for funding under the 9th call for projects of the French Competitiveness Clusters. Deinobiotics is aimed at screening the antibiotic and antifungal potential of Deinove's unique microbial library and at developing new molecules for treating resistant microbial infections, a high-priority medical need. The objective of this programme is to deliver at least one or two new compounds at the pre-IND stage... Deinove 's Press Release - communiqué de presse Deinove -

Deinove in brief

...Research of new antibiotics

Deinove discovered that several Deinococcus strains in its library produced antibiotics and antifungal agents. These preliminary results were encouraging enough to prompt the company to screen its whole collection. In fact, bacteria (and notably certain genera like the actinomycetes) are responsible for most of the currently marketed antibiotics. Infectious disease represents the world's leading cause of mortality. The dramatic increase in antibiotic resistance means that is is essential to rapidly discover and develop a new therapeutic arsenal... Deinove in brief -

Nosopharm
About Nosopharm

Nosopharm is a young biotech company who develops a novel biotecnological platform for the optimal exploitation of the exceptional medicinal potential of the microbial biodiversity. This platform affords us to:

- Discover and develop novel antibacterial molecules to cure antibiotic-multiresistant nosocomial infections, especially respiratory infections due to Gram-negative pathogens (Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Stenotrophomonas maltophilia, …)
- Make partnerships with companies willing to profit from their microbial bioresources for medicinal purpose, or willing to discover and characterize bioactive natural molecules that have never been described... About Nosopharm - à propos de Nosopharm -

Thursday, November 11, 2010

Cytheris : ORVACS Phase II Clinical Study Combines Immunomodulatory Intervention with Interleukin-7 (CYT107) and Antiretroviral Intensification...

CytherisParis – November 8, 2010 - ORVACS Phase II Clinical Study Combines Immunomodulatory Intervention with Interleukin-7 (CYT107) and Antiretroviral Intensification with Raltegravir and Maraviroc to Attack the Viral Reservoir of HIV Patients - Main hypothesis of this European study is that combination of the most potent and synergistic of antiretroviral drugs with immunomodulating agent may result in a decrease in HIV reservoirs and provide a means for the ultimate eradication of the virusORVACS (Objectif Recherche VACcin Sida) has launched a Phase II study designed to test the hypotheses that combination therapy with potent antiviral agents and immunomodulator can lead to a decrease in the HIV viral reservoirs and, ultimately, to eradication of the virus. The study is currently being conducted at clinical sites in France, Spain, Italy, and the United Kingdom.
Known as ERAMUNE 01, the Phase II clinical trial is scientifically coordinated by Christine Katlama as Principal Investigator, Brigitte Autran, Vincent Calvez and Dominique Costagliola from the University Pierre et Marie Curie and will use Cytheris’ investigative immunomodulatory agent, recombinant human interleukin-7 (CYT107), in combination with two potent antiretroviral drugs represented by the integrase inhibitor, raltegravir (ISENTRESS® - Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY™ - ViiV Healthcare). The main hypothesis of this study is that by combining the most potent and synergistic antiretroviral drugs, coupled with an immunomodulating agent capable of targeting or inducing activation of latently infected cells, the reservoirs of HIV can be decreased and, in the best case scenario, eradication of the virus may be feasible.
ERAMUNE 01 is sponsored by ORVACS and has been designed by the members of its international scientific advisory board. ORVACS is a non-profit organization based in Paris, France, that is supported and funded by the Bettencourt Schueller Foundation. The mission of ORVACS is to promote and conduct research on therapeutic vaccines and immunotherapeutic approaches in the field of AIDS. Created in 2001, ORVACS has a two-fold objective:
• The development of new therapeutic immunization strategies through clinical trials evaluating the safety, immunogenicity, and efficacy of new vaccines
• The pre-clinical development of new anti-HIV vaccine approaches
To optimize and further its mission, ORVACS has created a network of international academic research teams that are leaders in the field of immunology and antiretroviral therapy (ART) and on the development of innovative vaccine strategies against HIV. The objective of this vaccine therapy is to stimulate a weakened immune system and to amplify immune response.
The study is under the direction of Prof. Christine Katlama, MD (Principal Investigator), Head of the AIDS Clinical Research Unit, Department of Infectious Diseases, Hopital Pitie-Salpetriere, Paris, France.... [PDF] Cytheris' Press Release -

Wednesday, November 3, 2010

Medesis Pharma : Phase I Clinical Trial of NP01

Medesis Pharma2010-05-31 - Medesis Pharma, the French based pharmaceutical company, announces the successful completion of a phase I clinical trial of NP01, a first in class anti-diabetic for the treatment of type 2 diabetes mellitus.

The objective of this randomised, double blind, placebo controlled study was to evaluate the tolerability of NP01 in healthy male volunteers following single and repeat administration of 180ug of the drug’s active ingredient, vanadium.

The company reported that there were no serious adverse events and that the drug was well tolerated both after single and repeat administration...

[...]

...About Medesis Pharma

Medesis Pharma is a clinical stage pharmaceutical company specialising in the development of a wide range of therapeutic agents based upon propriety Aonys® drug delivery technology. Aonys® is particularly applicable to metal and oligonucleotide active ingredients... Medesis Pharma's Press Release -